WARISWarfarin Reinfarction Study |
| Authors: |
Smith P, Arnesen H, Holme I |
| Titles: |
The effect of warfarin on mortality and reinfarction after myocardial infarction |
| References: |
N Engl J Med 1990;323:147-52 |
| Disease: |
MI |
| Purpose: |
To determine the effects of warfarin on mortality, reinfarction and cerebrovascular events after MI |
| Study Design: |
Randomised, double-blind, placebo- controlled |
| Follow-up: |
Average 37 months |
| Patients: |
1214 patients (607 warfarin and 607 placebo), who had recovered from MI, aged < 75 years. Mean time since MI: 27 days |
| Treatmentregimen: |
Warfarin adjusted to prolong prothrombin time to achieve an international normalised ratio between 2.8 and 4.8 |
| Results: |
The total number of deaths was 94 patients in the warfarin group and 123 patients in the placebo group, representing a 24% reduction with warfarin (p = 0.02). Reinfarction occurred in 82 patients in the warfarin group and 124 patients in the placebo group, representing a 34% reduction with warfarin (p = 0.0001). Cerebrovascular events occurred in 20 patients in the warfarin group and 44 patients in the placebo group, representing a 55% reduction with warfarin (p = 0.0015) |
